OPM reports OPM-201 manufacturing and regulatory milestones
Oncodesign Precision Medicine said it completed micronization of the OPM-201 active ingredient and first technical batches of tablets, while EMA backed its proposed long-term toxicology strategy. The company also said MJFF paid an additional funding tranche under the LARKIN program.